

PLURISTEM THERAPEUTICS INC  
Form 8-K  
May 22, 2014

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report: May 22, 2014

PLURISTEM THERAPEUTICS INC.  
(Exact Name of Registrant as Specified in Its Charter)

Nevada  
(State or Other Jurisdiction of Incorporation)

001-31392  
(Commission File Number)

98-0351734  
(IRS Employer Identification No.)

MATAM Advanced Technology Park  
Building No. 5  
Haifa, Israel  
(Address of Principal Executive  
Offices)

31905  
(Zip Code)

011 972 74 710 7171  
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.07. Submission of Matters to a Vote of Security Holders.

Pluristem Therapeutics Inc. (the “Company”), held its annual meeting of stockholders on May 22, 2014. The results of the stockholder voting at the annual meeting are set forth below.

Stockholders voted on the matters set forth below:

Proposal No. 1 — Election of Directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

| Director Name    | For        | Against   | Abstain | Broker Non-Votes |
|------------------|------------|-----------|---------|------------------|
| Zami Aberman     | 15,225,574 | 3,653,462 | 26,907  | 15,245,366       |
| Israel Ben-Yoram | 18,611,618 | 130,728   | 163,597 | 15,245,366       |
| Isaac Braun      | 18,667,408 | 72,388    | 166,147 | 15,245,366       |
| Mark Germain     | 18,604,030 | 138,105   | 163,808 | 15,245,366       |
| Moria Kwiat      | 18,602,861 | 143,824   | 159,258 | 15,245,366       |
| Hava Meretzki    | 18,635,058 | 136,101   | 134,784 | 15,245,366       |
| Nachum Rosman    | 18,631,094 | 109,942   | 164,907 | 15,245,366       |
| Doron Shorrer    | 16,241,054 | 2,505,521 | 159,368 | 15,245,366       |

Proposal No. 2 — Amendment to the Company’s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock

| For        | Against   | Abstain | Broker Non-Votes |
|------------|-----------|---------|------------------|
| 30,674,537 | 2,725,415 | 177,798 | 573,559          |

Proposal No. 3 — Ratification of the selection of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2014

| For        | Against | Abstain | Broker Non-Votes |
|------------|---------|---------|------------------|
| 32,771,414 | 393,910 | 184,128 | N/A              |

The results reported above are final voting results.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PLURISTEM THERAPEUTICS INC.

Date: May 22, 2014

By: /s/ Boaz Gur-Lavie  
Name: Boaz Gur-Lavie  
Title: Chief Financial Officer and Secretary

---

---